DHEA (Dehydroepiandrosterone)
Endogenous adrenal androgen precursor (cholesterol → DHEA → androstenedione → Test). US-OTC, EU-Rx. Better evidence than Pregnenolone, but in young healthy men minimal Test elevation + ~15-20% E2 rise. WADA S1.1.b listed (banned).
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.
Related comparisons
Pregnenolone vs DHEAWHAT IS DHEA (DEHYDROEPIANDROSTERONE)?
Detailed overview
DHEA (Dehydroepiandrosterone) is an endogenous C19-steroid produced in the zona reticularis of the adrenal cortex – a pivotal androgen-precursor node in the steroidogenesis cascade. The biosynthesis pathway: cholesterol → pregnenolone (CYP11A1) → 17-OH-pregnenolone (CYP17A1) → DHEA (CYP17A1 17,20-lyase activity) → androstenedione (3β-HSD) → testosterone (17β-HSD). DHEA itself has weak androgenic activity, BUT at peripheral-tissue level (adipose, liver, prostate) the enzymatic conversion toward Test + DHT + Estradiol is meaningful. OTC supplement status is unusual: in the US, DHEA is freely sold as a dietary supplement under the 1994 DSHEA Act, while in EU member states (HU, DE, FR, IT) it is regulated as a prescription-only medication. In the AAS-PCT context the positioning of DHEA is contested: Wiehle 2014 (PMID 24913480) Phase II trial documented that in older men (>50 yr, low-baseline DHEA-S) a 100 mg/day × 6 month protocol produces a 5-10% serum-Test elevation alongside a parallel ~15-20% E2 rise. Morales 1994 (PMID 7910820) historical replacement trial showed similar results – BUT in young, healthy, normal-baseline-DHEA-S men the Test elevation is minimal or null, while aromatization triggers an E2 rise. Clinical bottom-line: DHEA has better evidence than Pregnenolone (closer-to-androgen step in the cascade), BUT in young, normal-HPG-axis users the benefit is limited + aromatization-risk persists. WADA S1.1.b Endogenous Anabolic Androgens explicitly listed – absolutely prohibited for competitive athletes (urine detection 7-14 days post-last-dose).
Mechanism
Endogenous adrenal C19-steroid precursor → peripheral conversion androstenedione → Test + E2
Dosing
25-50 mg/day oral, morning (mimic endogenous diurnal pattern). AAS-PCT upper range 50 mg.
Half-life
Parent DHEA ~25 min; DHEA-S (sulfate-conjugated active metabolite) ~10 hours.
Onset
Serum DHEA-S rise 1-2 hours after oral dose; Test-axis support measurable after 2-4 weeks chronic dosing.
Legal status
US: OTC dietary supplement (DSHEA 1994); EU (HU, DE, FR, IT): prescription-only medication. WADA S1.1.b banned.
Data console
Lab data
Safety
Side effects, stop signs, contraindications
Side effects · 8
- Androgenic effects (acne, oily skin, male-pattern hair loss) from peripheral DHEA to testosterone/DHT conversion in susceptible individuals.
- Virilization in women: voice deepening, hirsutism, clitoral enlargement, menstrual irregularity, because conversion has relatively greater effect on a woman's lower androgen baseline.
- Estrogenic effects via aromatization: roughly 15-20% E2 rise, which can provoke gynecomastia and water retention in gyno-sensitive men.
- Adverse lipid changes: moderate, dose-dependent decrease in HDL cholesterol with chronic use.
- Prostate effect in men over 50: DHT conversion may theoretically drive prostate growth and PSA rise, so PSA monitoring is warranted.
- Hepatic enzyme elevation (ALT/AST) is rare but documented with chronic high doses (over 50 mg/day for over 6 months); at low oral doses (under 50 mg/day) liver burden is minimal.
- Symptoms of hormonal imbalance: irritability, sleep disturbance, breast tenderness, and menstrual disruption in women.
- In young men with normal hormone levels, there is minimal or no testosterone increase while aromatization risk persists, making the risk-benefit ratio unfavorable.
Contraindications · 7
- Hormone-sensitive cancers (prostate, breast, uterine, ovarian) or suspicion thereof: absolute contraindication, because DHEA converts toward androgens/estrogens.
- Active prostate disease: severe benign prostatic hyperplasia (BPH, Qmax under 10 mL/s) or elevated PSA, due to DHT-mediated growth risk.
- Pregnancy and breastfeeding: absolute contraindication due to risk of fetal/infant androgen exposure.
- Competitive, drug-tested athletes: listed on WADA S1.1.b (endogenous anabolic androgens), banned in and out of competition; detectable in urine for 7-14 days.
- Predisposition to gynecomastia or prior gyno history without an aromatase inhibitor: the E2 rise can trigger symptoms; higher body fat (adipose aromatase) increases the risk.
- Pre-existing liver disease or unfavorable lipid profile (low HDL): chronic high doses can further worsen enzyme and lipid values, avoid without monitoring.
- Young user with normal hormone levels and no endocrine indication: benefit is minimal and hormonal side effects are disproportionate; in the EU (HU) it is in any case prescription-only.
Related Performance Compounds
Same therapeutic category
Studies
Related research and clinical findings
The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women.
Morales AJ, Haubrich RH, Hwang JY, Asakura H, Yen SS
Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age.
Morales AJ, Nolan JJ, Nelson JC, Yen SS
Replacement of DHEA in aging men and women. Potential remedial effects.
Yen SS, Morales AJ, Khorram O
DHEA replacement in patients with adrenal insufficiency
Allolio B, Arlt W, Hahner S.
Telegram
Have a question about DHEA (Dehydroepiandrosterone)?
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.